3M to pay $6 billion as Combat Arms Earplug settlement nears final resolution
By Tomi Kilgore
Payments will be made through 2029 to resolve the litigation
3M Co. said Tuesday the Combat Arms Earplug litigation is nearing its final resolution, with the consumer, industrial and healthcare-products company agreeing to pay up to $6 billion to settle all claims.
The settlement is the final chapter of a fight that's been going on for years, in which the maker of Post-it Notes, Scotch tape and N95 masks was sued by hundreds of thousands of plaintiffs who said the 3M earplugs caused hearing loss.
On Tuesday, 3M (MMM) said that, out of 293,000 claims, more than 249,000 claimants have registered to participate. More than 41,000 claims were dismissed by courts. Once all the settlement registrations have been submitted, 3M believes the settlement will achieve a more than 99.9% participation level.
3M said it will make its payments between 2023 to 2029. On a pre-tax, present-value basis, the settlement is valued at $5.3 billion, which the company has already recorded reserves.
The stock was little changed in premarket trading.
3M and Aearo, the company 3M acquired in 2008 that made the earplugs, are "actively engaged" in insurance-recovery activities to offset part of the settlement payments.
3M's stock has fallen 4.1% year to date, while the Dow Jones Industrial Average has gained 4.3%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-26-24 0751ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth